Eckert & Ziegler (EUZ) Q4 2025 earnings summary

Executive summary

• Revenue reached €312.0 million in 2025, a new record and a 5% increase year-over-year, driven by strong growth in radiopharmaceuticals.

• Net income rose to €49.2 million, up 44% from the previous year, with EPS at €0.78.

• The company maintained its strategic focus on expanding its global market position in radioisotope products and services, with significant investments in production and regulatory milestones.

• The board expressed high satisfaction with operational and financial performance, highlighting resilience against currency headwinds and a cyberattack.

Financial highlights

• Revenue increased by €16.1 million to €312.0 million, with radiopharmaceuticals up 16% to €145.5 million year-over-year.

• Net income from continuing operations was €49.2 million, up €8.4 million from the prior year.

• Adjusted EBIT rose 18% to €77.7 million; gross profit increased by €9.8 million to €153.0 million.

• Cash flow from operations decreased by €25.6 million to €58.4 million due to higher working capital needs.

• Equity ratio improved to 55% (prior year: 51%), with equity up €28.2 million to €253.4 million.

Outlook and guidance

• For 2026, revenue is expected to reach €320 million and adjusted EBIT €80 million, assuming a USD/EUR rate of 1.20.

• Segment Medical anticipates continued strong demand, with external revenue forecast at €165 million and adjusted EBIT at €49 million.

• Segment Isotope Products expects a recovery with external revenue of €155 million and adjusted EBIT of €33 million.

• The company expects to benefit from ongoing market growth in radiopharmaceuticals and new product launches.